Azenta/$AZTA
1D1W1MYTD1Y5YMAX
Capital at risk
About Azenta
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
- Ticker
- $AZTA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,900
- Headquarters
- Burlington, United States
- Website
- www.azenta.com
Azenta Metrics
BasicAdvanced
$1.4B
-
-$2.70
1.38
-
Price and volume
Market cap
$1.4B
Beta
1.38
52-week high
$41.73
52-week low
$15.93
Average daily volume
801K
Financial strength
Current ratio
2.5
Quick ratio
1.85
Long term debt to equity
0.036
Total debt to equity
0.036
Profitability
EBITDA (TTM)
33.006
Gross margin (TTM)
44.06%
Net profit margin (TTM)
-20.02%
Operating margin (TTM)
-3.70%
Effective tax rate (TTM)
26.38%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
-0.73%
Return on equity (TTM)
-7.04%
Valuation
Price to revenue (TTM)
2.39
Price to book
0.93
Price to tangible book (TTM)
1.6
Price to free cash flow (TTM)
148.441
Free cash flow yield (TTM)
0.67%
Free cash flow per share (TTM)
0.216
Growth
Revenue change (TTM)
4.78%
Earnings per share change (TTM)
6.15%
3-year revenue growth (CAGR)
-0.88%
10-year revenue growth (CAGR)
1.13%
3-year earnings per share growth (CAGR)
70.09%
10-year earnings per share growth (CAGR)
9.62%
What the Analysts think about Azenta
Analyst ratings (Buy, Hold, Sell) for Azenta stock.
Analyst projections of the future price of Azenta stock.
Bulls say / Bears say
Q3 revenue rose 12% year-over-year to $161 million, demonstrating robust top-line momentum despite challenging market conditions (Reuters via Bitget News: Bitget News)
Adjusted EBITDA margin recovered to 11.4% in Q3 from 5.4% in the prior quarter, highlighting successful operational leverage improvements (Reuters via Bitget News: Bitget News)
The company ended Q3 with $529 million in cash and marketable securities and no outstanding debt, enabling a $50 million share repurchase under its 2025 program (Reuters via Bitget News: Bitget News)
Gross margin contracted to 44.9%, down 130 basis points year-over-year due to quality remediation and fixed-cost absorption challenges in Automated Stores (Nasdaq)
Organic revenue in Q2 fell 3% year-over-year, reflecting uneven demand across both Sample Management Solutions and Multiomics (Nasdaq)
Azenta recorded a $149 million non-cash goodwill impairment in Q2, signaling overvaluation of acquired assets and lingering underperformance in Multiomics (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 24 Aug 2026.
Azenta Financial Performance
Revenues and expenses
Azenta Earnings Performance
Company profitability
Upcoming events
No upcoming events
Azenta News
AllArticlesVideos
Funds containing Azenta
AllUSDGBPEUR
Fund name | Fund size | $AZTA weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.07% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.07% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.04% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.04% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.